© 2024 New Atlas

Biogen

  • Biogen has abandoned late-stage clinical trials for a previously promising Alzheimer's drug
    Medical
    Another big Alzheimer’s drug fails in late-stage human trials
    A shockwave hit the Alzheimer’s research community today after Biogen announced it was discontinuing two massive final phase human trials into the promising Alzheimer’s drug aducanumab. The announcement is the latest in a long line of failed Alzheimer’s drugs targeting the amyloid hypothesis.